Cardiostimulant effects of urotensin-II in human heart in vitro.
about
Is urotensin-II the new endothelin?The role of urotensin II in cardiovascular and renal physiology and diseasesElevated plasma levels of human urotensin-II immunoreactivity in congestive heart failureThe G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Urotensin II inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signallingInotropic action of the puberty hormone kisspeptin in rat, mouse and human: cardiovascular distribution and characteristics of the kisspeptin receptorGSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivoIdentification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin IIUrotensin-II receptor stimulation of cardiac L-type Ca2+ channels requires the βγ subunits of Gi/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C β1 isoform.Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisationUrotensin-II and the cardiovascular system--the importance of developing modulators.Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S PathwayIs plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome?Urotensin II in cardiovascular regulation.Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium.PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration.Biochemical modulation of the sleep-wake cycle: endogenous sleep-inducing factors.Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease.Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension.Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.Neuronostatin, a novel peptide encoded by somatostatin gene, regulates cardiac contractile function and cardiomyocyte survival.Decrease of Urotensin II activity can impact on the volume status in predialysis chronic kidney disease.Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain.Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats.Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile.Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and ERK1/2-independent TGF-β1 in neonatal cardiac fibroblasts.Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat.
P2860
Q24672927-6C1EF367-5A06-4403-BF99-11DE93E74CEFQ24675590-0DF30299-81AD-4941-9CCD-C4D4AB0B6825Q28177421-CD47F348-4AE0-4CF1-820D-976C6346BE36Q33599835-CF3FE0FA-E37C-4882-8A14-95DB2A4E476AQ33991646-C24761B9-6722-48F0-8333-4A3F1730AA9EQ34087759-770B4DDC-64DB-45D2-801F-521A269992FCQ34233981-FF083814-DBD3-4BBC-A601-A0D357C8D3B2Q35047377-697B9D18-61B8-4179-9414-2DA0529F8E47Q35048941-BCEE9E9A-F198-49A7-BE7F-34780CA2DE78Q35221658-07183FBA-EB17-4AFA-B5F2-3D81EF255778Q35545386-778E3638-15E4-489F-BD39-20FC507EEFE6Q35779239-00F25532-E240-4BC1-A475-2E0A7D45B0C4Q35813861-3F8F303A-CFBF-4F0C-9D2D-675932CF8C02Q36105692-8C93E79E-0E08-4F4A-A0BD-794796D1465FQ37344439-06DEE686-D55B-4FD9-8031-D08A5A3BA553Q37394539-DA577F5D-9FC2-4D2F-8BBC-F0FBBDC7E302Q37422701-15D47D29-FFE6-4B2E-945A-7295E900D4C6Q37873882-5DBC4414-05A5-4130-BF60-989051B0EAABQ40122555-FDF95479-F57F-4052-89A3-46CB3CF7A12EQ40166897-4C92A3E6-518F-4008-A14F-7943ED23B126Q40430686-68EB30BE-525D-4305-9897-1A6B78483CAAQ40644520-8E389D7C-9381-4ACE-9C9A-454D0B3815FEQ40735770-9F336E57-AF94-4EAA-987A-A21892383777Q41222834-063F2904-5C89-4F64-91F5-ADAE256ECDFDQ41548461-385DC4B3-3523-4B05-8A25-B6FAD3A6FC2CQ41819007-B09CB6AC-FDE0-4092-B8C5-D4A23386A0DAQ41981084-70BA6465-0DF8-458B-9666-8546B092DFBDQ42215972-3D6E51C6-FEAB-41D6-99AB-7C9A82DAB073Q43263666-7AFB13E4-AA23-42F3-B549-93BF8260D425Q43268409-BB3FEE7B-F8AB-4E0D-A95A-4C0ADB4E03C8Q44654245-ADCFE7A4-CE7B-48F6-A26F-35C2E3BB373FQ54643074-A6C2E084-FFE6-4DB5-ABF6-EF2FAAA81579Q54708765-0FC15D28-B15D-4A21-83F0-896686FBFD04
P2860
Cardiostimulant effects of urotensin-II in human heart in vitro.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cardiostimulant effects of urotensin-II in human heart in vitro.
@en
type
label
Cardiostimulant effects of urotensin-II in human heart in vitro.
@en
prefLabel
Cardiostimulant effects of urotensin-II in human heart in vitro.
@en
P2093
P2860
P356
P1476
Cardiostimulant effects of urotensin-II in human heart in vitro.
@en
P2093
D M O'Brien
F D Russell
P Molenaar
P2860
P356
10.1038/SJ.BJP.0703811
P407
P577
2001-01-01T00:00:00Z